VLU Dressing Study

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

31 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-08-22

Study Completion Date

2023-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of the study is to investigate the effectiveness of Cutimed Sorbact (Study Device) in modifying bacterial load in venous leg ulcers (VLU).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate the Clinical Effectiveness of a Collagen-ORC Antimicrobial Matrix in Venous Leg Ulcers

NCT00235209

Leg Ulcer

COMPLETED PHASE4

AQUACEL® Ag+ Extra™ and Cutimed™ Sorbact® Dressing in the Management of Venous Leg Ulcers Over a 12-week Period

NCT05892341

Venous Leg Ulcer Diabetic Foot

COMPLETED NA

Effectiveness of Sorbion in the Treatment of Venous Leg Ulcers The Protocol Elements

NCT03020446

Venous Wound Ulcers

TERMINATED NA

Effectiveness of a Hydrophobic Dressing for Microorganisms' Colonization and Infection Control of Vascular Ulcers

NCT03667937

Venous Leg Ulcer Bacterial Infections Chronic Ulcer of Skin of Lower Limb Nos

UNKNOWN PHASE4

Activated Carbon Interphase Effect on Biofilm and Total Bacterial Load

NCT03461783

Wound Infection

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Venous Leg Ulcer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Due to the nature of the study and products, investigator blinding is unrealistic and subject blinding is unlikely. Research staff will avoid naming the dressing or suggesting the assignment to the subjects. However, an independent monitor with experience in treating wounds will be blinded to the treatment assignment and will confirm healing outcomes based on images.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cutimed® Sorbact®

Participants in this group will receive the Cutimed Sorbact intervention for 6 weeks.

Group Type EXPERIMENTAL

Cutimed® Sorbact®

Intervention Type DEVICE

Dialkylcarbomoyl chloride based wound dressing

Acticoat®

Participants in this group will receive the Acticoat intervention for 6 weeks.

Group Type ACTIVE_COMPARATOR

Acticoat®

Intervention Type DEVICE

Silver impregnated contact layer dressing

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cutimed® Sorbact®

Dialkylcarbomoyl chloride based wound dressing

Intervention Type DEVICE

Acticoat®

Silver impregnated contact layer dressing

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Adults, 18 years old and older (i.e. age ≥ 18 years).
2. Venous leg ulcer (VLU) is present on the leg. VLU shall be full thickness but without exposure of deeper tissues (muscle bone or tendon).
3. If more than one ulcer is present, the largest ulcer meeting criteria shall be designated the study ulcer.
4. If more than one ulcer on the study ulcer limb, study ulcer shall be at least one centimeter from other ulcers.
5. Venous Doppler ultrasound exam, within one year from randomization, shall demonstrate reflux of over 0.5 seconds in the affected limb.
6. Ankle-Brachial Pressure Index (ABI) exam with value of ≥0.80 in the affected limb
7. VLU has been treated with silver based therapy for at least 2 weeks within the previous 6 months.
8. VLU present for at least one month prior to screening visit 1.
9. VLU at least 2 cm2 in size but not larger than 100 cm2.
10. After debridement, study ulcer demonstrates a clean wound bed.
11. If subject is a female of childbearing potential, subject must use at least one method of contraception acceptable by PI such as birth control pills, Intrauterine Device (IUD), condoms, or sexual abstinence. At visit 1 urine pregnancy test must be negative.
12. Subject is able to comprehend all study related procedures and adhere to study schedule.
13. Subject is able to provide written informed consent.

Exclusion Criteria

1. Based on investigator medical judgment, ulcer is caused by any etiology exclusive of venous insufficiency.
2. Study Ulcer surface area (post-debridement) has increased or decreased by more than 30% in the period between screening visit 1 and treatment visit 1.
3. Study Ulcer exhibits clinical signs and symptoms of infection in the period between screening visit 1 and treatment visit 1 requiring oral antibacterial therapy.
4. Subject has known allergy to any of the materials used in the study.
5. Subject is unable to tolerate multi-layer compression therapy.
6. Based on investigator medical judgment, the Study Ulcer is suspicious for cancer (e.g. basal cell carcinoma or squamous cell carcinoma).
7. In the month prior to screening visit 1 subject was treated with systemic immunosuppressive medications for more than 2 weeks (e.g. chemotherapy, corticosteroids), and/or it is anticipated subject will require such medications during study period.
8. In the month prior to screening visit 1 subject was enrolled in any other research protocol for treatment of Study Ulcer.
9. The Subject has been diagnosed with malignant disease not in remission over the 5 years immediately preceding screening visit 1. (Except: cervical carcinoma in situ, cutaneous squamous cell carcinoma, cutaneous basal cell carcinoma that have been treated and have no evidence of recurrence or metastases).
10. Study ulcer area has been treated with radiation therapy at any time.
11. In the opinion of PI the subject has a medical condition such as autoimmune, renal, hepatic or hematologic disease that makes the subject an inappropriate candidate for participation in study.
12. In the month preceding screening visit 1 Study Ulcer has been treated with advanced tissue engineered devices matrix based devices (e.g., Apligraf, Dermagraft, Oasis).
13. Subject is diagnosed with New York Heart Association Class III and IV congestive heart.
14. Failure: Class III: Symptoms with moderate exertion or, Class IV: Symptoms at rest.
15. Subject is diagnosed with diabetes mellitus that is poorly controlled and shall be defined as hemoglobin A1C \>10%.
16. Study Ulcer is completely or more than 50% of the Study Ulcer is located on the foot (i.e. below the malleolus).
17. Subject is a female of childbearing potential, and refusing to use at least one method of contraception acceptable by PI such as birth control pills, IUD, condoms, or sexual abstinence.
18. Positive pregnancy test in screening visit 1 in a female of childbearing potential or active pregnancy or breast-feeding.
19. In the opinion of the PI the subject is unable to understand or comply with study related protocol including but not limited to providing informed consent.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No